- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00884325
Management of Pruritus With Xyzal in Atopic Dermatitis
August 14, 2013 updated by: Leon Kircik, M.D., Derm Research, PLLC
Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study
It is historically well known that the management of pruritus in atopic dermatitis is very difficult.
Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra.
It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- DermResearch, PLLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatient, male or female subjects of any race, at least 18 years of age.
Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study. A female is considered of childbearing potential unless she is:
- postmenopausal for at least 12 months prior to study drug administration;
- without a uterus and/or both ovaries; or
- has been surgically sterile for at least 6 months prior to study drug administration.
Reliable methods of contraception are:
- hormonal methods or intrauterine device in use > 90 days prior to study drug administration;
- barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
- vasectomized partner. [Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.]
- Definitive diagnosis of atopic dermatitis as per Rajka-Hanifin criteria.
- Visual Analog Scale (VAS) pruritus score of 6 cm or more (moderate to severe itching) at baseline.
- Willing to refrain from other antihistamines and topical steroids and topical immunomodulators for the duration of the study.
- Able to understand and comply with the requirements of the study and sign Informed Consent/Health Insurance and Portability Accountability Act (HIPAA) Authorization forms.
Exclusion Criteria:
- Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
- Requiring oral treatment for their atopic dermatitis apart from oral antihistamines
- History of hypersensitivity or idiosyncratic reaction to to any component of the test medication , or to cetirizine.
- Atopic Dermatitis triggered by an unavoidable irritant/allergen.
- Skin disease/disorder that might interfere with the diagnosis or evaluation of atopic dermatitis (e.g., erythroderma, skin infection on the affected area, etc.)
- Non-compliance with the proper wash-out periods for prohibited medications.
- Uncontrolled chronic disease such as diabetes
- The presence of renal disease with mild, moderate or severe renal impairment
- Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.
- Clinically significant alcohol or drug abuse, in the opinion of the Investigator.
- History of poor cooperation, non-compliance with medical treatment, or unreliability.
- Participation in an investigational drug study within 30 days of the Baseline Visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
One tablet taken orally at night for 28 days
|
Experimental: Xyzal
|
One tablet 5 mg taken orally at night for 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pruritus VAS Scores at Baseline, Week 2 and Week 4
Time Frame: Baseline - Week 2-Week 4
|
Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days.
Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities.
|
Baseline - Week 2-Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4
Time Frame: Baseline - Week 2 - Week 4
|
Consented subjects who met inclusion/exclusion criteria were asked to complete a DLQI (Dermatology Life Quality Index)at Baseline, Week 2 and Week 4. The DLQI is a 10 item questionnaire broken down into 6 domains; symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment with a total score ranging from 0-30 (no effect on subject's life for 0, extremely large effect on subject's life for 30)
|
Baseline - Week 2 - Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Leon H. Kircik, M.D., DermResearch, PLLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
January 1, 2010
Study Registration Dates
First Submitted
April 17, 2009
First Submitted That Met QC Criteria
April 17, 2009
First Posted (Estimate)
April 20, 2009
Study Record Updates
Last Update Posted (Estimate)
August 16, 2013
Last Update Submitted That Met QC Criteria
August 14, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Hypersensitivity
- Skin Manifestations
- Skin Diseases, Eczematous
- Dermatitis
- Eczema
- Pruritus
- Dermatitis, Atopic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Levocetirizine
Other Study ID Numbers
- XYZ0801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pruritus
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Toray Industries, IncCompletedUremic PruritusBulgaria, Germany
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
Thammasat University HospitalCompletedUremic PruritusThailand
-
Conmed Pharmaceutical & Bio-Medical CorporationChang Gung Memorial Hospital; Kaohsiung Medical University; Tri-Service General... and other collaboratorsCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Kissei Pharmaceutical Co., Ltd.Maruishi PharmaceuticalCompleted
-
Chang Gung Memorial HospitalUnknown
-
Lumosa Therapeutics Co., Ltd.Unknown
-
RDD Pharma LtdWithdrawn
Clinical Trials on Levocetirizine dihydrochloride (Xyzal)
-
IPCA Laboratories Ltd.Completed
-
UCB PharmaCompletedSeasonal Allergic RhinitisUnited States
-
Bridgette JonesNational Institutes of Health (NIH)RecruitingAllergic AsthmaUnited States
-
UCB PharmaCompletedSeasonal Allergic RhinitisUnited States
-
AAADRS Clinical Research CenterUCB PharmaCompletedPerennial Allergic RhinitisUnited States
-
Association Asthma, BulgariaUCB PharmaCompleted
-
Hospices Civils de LyonCompletedChronic Spontaneous Urticaria
-
Dr. Reddy's Laboratories LimitedCompleted
-
UCB PharmaCompletedAllergic Rhinitis | Chronic UrticariaUnited States
-
Dr. Reddy's Laboratories LimitedCompleted